Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease
1Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Insights
The VOLTAIRE-CD study found that the biosimilar BI 695501 demonstrated comparable efficacy and safety to adalimumab in treating Crohn's disease. Both treatments showed similar improvements in symptoms and side effect profiles.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
What Is This Summary About?:
This is a summary of the VOLTAIRE-CD study originally published in The Lancet Gastroenterology and Hepatology. BI 695501 is a medicine being developed to treat people with moderately to severely active Crohn's disease, a chronic inflammatory condition that usually affects the small bowel and colon. BI 695501 is a biosimilar, which means that it is designed to be highly similar to the original drug. The VOLTAIRE-CD study aimed to show whether BI 695501 is just as effective and safe as the original drug, adalimumab (Humira®) in treating Crohn's disease.
What Were The Results?:
Participants in the VOLTAIRE-CD study took either the original adalimumab product for 24 weeks followed by BI 695501 for the next 22 weeks, or just the biosimilar BI 695501 for the entire 46-week treatment period. Similar improvements in Crohn's disease symptoms and the number of participants with side effects were similar, regardless of whether they received the original drug or BI 695501.
What Do The Results Of The Study Mean?:
These results show that both drugs could be used in the treatment of people with Crohn's disease, with similar efficacy and safety.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids


